LENZ Therapeutics (LENZ) Net Equity Issued and Repurchased (2020 - 2025)

LENZ Therapeutics (LENZ) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $26.1 million in Q2 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 832.53% year-over-year to $26.1 million in Q2 2025; TTM through Dec 2025 was $26.1 million, a 67.18% decrease from a year earlier, with the FY2024 full-year figure at $79.5 million, changed N/A from the prior year.
• Net Equity Issued and Repurchased for Q2 2025 stood at $26.1 million, up from -$85000.0 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for LENZ reached as high as $165.6 million in Q1 2021 and fell as low as -$83.0 million in Q3 2023.
• Historically, Net Equity Issued and Repurchased has averaged $30.3 million across 4 years, with a median of $21.5 million in 2023.
• Across the five-year window, Net Equity Issued and Repurchased slumped 120.99% in 2024 and jumped 832.53% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $14.8 million in 2021, then plunged by 659.85% to -$83.0 million in 2023, then soared by 99.9% to -$85000.0 in 2024, then jumped by 30805.88% to $26.1 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $26.1 million in Q2 2025, -$85000.0 in Q4 2024, and $29.8 million in Q3 2024.